Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa

Letters in Applied Microbiology

Volumn 56, Issue 2, 2013, Pages 149-154

  Nair, C G ^a   Chao, C ^a   Ryall, B ^a,b   Williams, H D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibiotic resistance; Bronchiectasis; Cystic fibrosis; Mutation frequency; Oxidative stress

Indexed keywords

BIOLOGICAL ORGANS; ESCHERICHIA COLI; MUTAGENESIS; PATHOGENS; PATIENT TREATMENT;

ANTIBIOTIC THERAPY; ANTIBIOTICS RESISTANCE; BRONCHIECTASIS; CHRONIC INFECTION; CYSTIC FIBROSIS; EXPOSED TO; LETHAL CONCENTRATION; MUTATION FREQUENCY; PS. AERUGINOSA; PSEUDOMONAS AERUGINOSA;

ANTIBIOTICS;

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; GENTAMICIN; HYDROXYL RADICAL; KANAMYCIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; THIOUREA; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; BACTERIUM; COLONIZATION; CONCENTRATION (COMPOSITION); HYDROXYL RADICAL; INFECTIVITY; MUTAGENICITY; MUTATION; PATHOGEN; SUBLETHAL EFFECT;

ADAPTIVE RADIATION; ARTICLE; BACTERIAL MUTATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EXPOSURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ESCHERICHIA COLI; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84872396950     PISSN: 02668254     EISSN: 1472765X     Source Type: Journal    
DOI: 10.1111/lam.12032     Document Type: Article

References (24)

1. Bals, R., Hubert, D. and Tummler, B. (2011) Antibiotic treatment of CF lung disease: from bench to bedside. J Cyst Fibros 10(Suppl 2), S146-S151.
2. Bendiak, G.N. and Ratjen, F. (2009) The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med 30, 587-595.
3. Campodonico, V.L., Gadjeva, M., Paradis-Bleau, C., Uluer, A. and Pier, G.B. (2008) Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med 14, 120-133.
4. Cystic Fibrosis Trust (2010) Cystic Fibrosis Trust Annual Data Report 2010. Bromley, Kent: Cystic Fibrosis Trust.
5. Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B. and Gibson, R.L. (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34, 91-100.
6. Foti, J.J., Devadoss, B., Winkler, J.A., Collins, J.J. and Walker, G.C. (2012) Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. Science 336, 315-319.
7. Foweraker, J. (2009) Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br Med Bull 89, 93-110.
8. Harrison, F., Browning, L.E., Vos, M. and Buckling, A. (2006) Cooperation and virulence in acute Pseudomonas aeruginosa infections. BMC Biol 4, 21.
9. Hauser, A.R., Jain, M., Bar-Meir, M. and McColley, S.A. (2011) Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 24, 29-70.
10. Kaufmann, B.B. and Hung, D.T. (2010) The fast track to multidrug resistance. Mol Cell 37, 297-298.
11. Koch, C. and Hoiby, N. (1993) Pathogenesis of cystic fibrosis. Lancet 341, 1065-1069.
12. Koch, C. and Hoiby, N. (2000) Diagnosis and treatment of cystic fibrosis. Respiration 67, 239-247.
13. Kohanski, M.A., Dwyer, D.J., Hayete, B., Lawrence, C.A. and Collins, J.J. (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130, 797-810.
14. Kohanski, M.A., DePristo, M.A. and Collins, J.J. (2010) Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell 37, 311-320.
15. Langton Hewer, S.C. and Smyth, A.R. (2009) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev doi: 10.1002/14651858.CD004197.pub3.
16. Mendelman, P.M., Smith, A.L., Levy, J., Weber, A., Ramsey, B. and Davis, R.L. (1985) Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 132, 761-765.
17. Moriarty, T.F., McElnay, J.C., Elborn, J.S. and Tunney, M.M. (2007) Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 42, 1008-1017.
18. Oliver, A., Canton, R., Campo, P., Baquero, F. and Blazquez, J. (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288, 1251-1254.
19. Schaedel, C., de Monestrol, I., Hjelte, L., Johannesson, M., Kornfalt, R., Lindblad, A., Strandvik, B., Wahlgren, L. et al. (2002) Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 33, 483-491.
20. Smith, E.E., Buckley, D.G., Wu, Z., Saenphimmachak, C., Hoffman, L.R., D'Argenio, D.A., Miller, S.I., Ramsey, B.W. et al. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103, 8487-8492.
21. Tunney, M.M., Field, T.R., Moriarty, T.F., Patrick, S., Doering, G., Muhlebach, M.S., Wolfgang, M.C., Boucher, R. et al. (2008) Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 177, 995-1001.
22. Williams, H.D. and Davies, J.C. (2012) Basic science for the chest physician: Pseudomonas aeruginosa and the cystic fibrosis airway. Thorax 67, 465-467.
23. Williams, H.D., Ziosnik, J.E.A. and Ryall, B. (2007) Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa. Adv Microb Physiol 5252, 1-71.
24. Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A., Meyer, K.C., Birrer, P., Bellon, G. et al. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109, 317-325.